SC: Menstrual Health is a Fundamental Right under Article 21; Orders Free Sanitary Pads in Schools  ||  Supreme Court: Industrial Court is the Proper Forum to Decide Issues Relating to Contract Labour  ||  Supreme Court: Only Civil Court of Original Jurisdiction Can Extend Arbitral Tribunal’s Mandate  ||  SC: Demolition of Private Property Must Rest on Clear Statutory Grounds and Due Consideration  ||  SC: After Complaint Was Withdrawn, BCI Disciplinary Committee Could Not Penalise Advocate  ||  MP HC: Decree Holder Cannot Defeat Compromise or Initiate Execution by Refusing Debtor’s Cheque  ||  MP HC: Spouse’s Income Cannot Be Clubbed With Public Servant’s for Disproportionate Assets Case  ||  Ker HC: Bar Association is Not Employer & Cannot Form Internal Complaints Committee under POSH Act  ||  SC: Ex-Contract Workers Must Be Preferred When Employers Replace Contract Labour With Regular Staff  ||  SC: Waqf Tribunals Cannot Hear Claims over Properties Not Listed or Registered under Waqf Act    

Roche Products v. Drugs Controller General of India and ors - (High Court of Delhi) (25 Apr 2016)

Delhi High Court to delve into Drug Controller irregularities

Civil

The Delhi High Court deferred a dispute regarding the development, classification and promotion of bio-similar drugs to 2 June 2016. Brought by Roche Products, the plaint raised concerns about irregularities by the Drug Controller General of India in granting approval to Biocon Limited and Mylan Pharmaceuticals for a bio-similar drug in five days - a process which usually takes much longer than that due to deliberation by three separate bodies, before it reaches the DCGI. The drug in question is Trastuzumab, used for treatment of breast cancer.

The Court accepted Roche’s arguments, ruling that “approvals…are not on the basis of the adherence of the Guidelines of 2012 and rules framed”. However, final finding would be arrived at upon completion of trial. The Defendants were allowed to continue manufacturing and marketing their drug claiming bio-similarity with Roche’s drug, but with certain provisos on indication used on packaging.

Tags : TRASTUZUMAB   BIO-SIMILAR   DCGI   ROCHE  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved